Revvity Inc/ US7140461093 /
2024-05-20 4:31:45 PM | Chg. +1.29 | Volume | Bid4:31:47 PM | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
111.55USD | +1.17% | 7,669 Turnover: 848,501.53 |
111.44Bid Size: 100 | -Ask Size: - | 13.77 bill.USD | 0.25% | 20.07 |
GlobeNewswire
05-09
Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific N...
GlobeNewswire
01-19
Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Pan...
GlobeNewswire
01-08
Pleno Deploys its RAPTOR Instrument Platform Available with TotalSeq™ Antibodies from BioLegend
GlobeNewswire
2023-11-30
Study Shows that OGM Plays an Important Role in Efficient Diagnosis of FSHD
GlobeNewswire
2023-11-13
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revvity, Inc. -...
GlobeNewswire
2023-11-05
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revvity, Inc. - ...
GlobeNewswire
2021-05-18
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in the UK COVID-19 Human Challenge Study...
GlobeNewswire
2021-05-11
Oxford Immunotec’s T-SPOT.COVID Test is Used in the COV-AD Clinical Study to Investigate the Immunol...
GlobeNewswire
2021-04-29
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell R...